Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

d clinical trial and NDA expenses 801,679 2,776,543

Other accrued expenses 1,411,523 330,441

Accrued interest payable 20,391 22,756

Short-term lease payable 8,142 7,259

Short-term notes payable - related party 2,000,000 -

Total current liabilities 14,514,875 5,822,750

Long-term lease payable 6,595 12,818

Long-term grant payable 500,000 500,000

Long-term notes payable - related party - 2,000,000

Line of credit 3,915,000 3,915,000

Total liabilities 18,936,470 12,250,568

COMMITMENTS AND CONTINGENCIES

MINORITY INTEREST - -

STOCKHOLDERS' EQUITY (DEFICIT):

Common stock, $0.01 par value - 60,000,000

shares authorized; 40,805,932 issued and

outstanding at September 30, 2008; 38,502,987

shares issued and outstanding at

December 31, 2007 408,059 385,030

Additional paid-in capital 109,416,354 106,859,532

Deficit accumulated during the

development stage (119,613,300) (99,583,588)

Total stockholders' equity (deficit) (9,788,887) 7,660,974

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

(DEFICIT) $9,147,583 $19,911,542

ADVANCED LIFE SCIENCES HOLDINGS, INC. AND SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three months ended

September 30,


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... 2011 Reportlinker.com announces that a new market ... Global Biotechnology Reagents Industry ... report analyzes the worldwide markets for Biotechnology Reagents ... Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, ...
... Feb. 23, 2011 Ingenuity® Systems, a leading ... science researchers, today announced a research collaboration with ... sequencing (NGS) data analysis. Covance Genomics Laboratory, a ... discovery and development industry, and Ingenuity will work ...
... State University have developed a faster, easier way ... by using liquid metal. Microfluidic devices manipulate small ... of applications, from testing minute blood samples to ... easier to incorporate electrodes into microfluidic devices, we ...
Cached Biology Technology:Reportlinker Adds Global Biotechnology Reagents Industry 2Ingenuity Systems and Covance Collaborate to Support Next-Generation Sequencing Research 2Liquid metal key to simpler creation of electrodes for microfluidic devices 2
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
(Date:7/24/2014)... Neiker-Tecnalia is currently conducting research into the potato genes ... characterised by a reduction in rainfall and increased extremes ... the most resistant genes in order to create new ... conditions.The research is also seeking to find out how ... of greater drought and higher and lower temperatures. , ...
(Date:7/24/2014)... German . ... sufferers worldwide, a further 600 million people living with ... population contending with allergic rhinitis (allergic inflammation of the ... organs and parts of the body beyond the respiratory ... form of inflammatory bowel diseases such as colitis ulcerosa), ...
Breaking Biology News(10 mins):A tiny new species of frog from Brazil with a heroic name 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3
... of Genes & Development, Dr. Karlene Cimprich and colleagues ... sufficient to activate the ATR-mediated DNA damage checkpoint. ... Dr. Cimprich. "The ability to precisely define and manipulate ... experimental system will enable us to control, quantitative and ...
... to preserve grapes could help prevent allergies and boost healthy ... & Industry, the magazine of the SCI. The same technique ... wines without the added sulphites that can cause asthma and ... remain in storage for months and are usually treated with ...
... knowledge of the properties and actions of enzymes, scientists have ... originally isolated from blue-green algae. , This accomplishment is ... promising drugs for use in clinical trials. , In ... of the journal ACS Chemical Biology, a scientific team lead ...
Cached Biology News:Grape expectations for healthier wine 2Turning green gunk to gold, anti-cancer gold 2
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
... shakers combine high durability and capacity with ... heavy-duty mechanism prevents vibration, allowing the unit ... Every other part, from the large rubber ... machined aluminum platform is designed to last ...
...
Biology Products: